NCT05233579View on ClinicalTrials.gov

Open-Label Trial of Sulforaphane in Premutation Carriers With FXTAS

NACompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

June 25, 2021

Primary Completion Date

January 1, 2023

Study Completion Date

January 1, 2023

Conditions
Fragile X Associated Tremor/Ataxia Syndrome (Fxtas) (Diagnosis)
Interventions
DIETARY_SUPPLEMENT

Sulforaphane

Sulforaphane will be taken one tablet in the morning with breakfast and then every 2 weeks, the dose will be increased by one tablet until a total of 6 tablets are taken in the morning. The supplement should be taken around the same time each day.

Trial Locations (1)

95817

UC Davis MIND Institute, Sacramento

All Listed Sponsors
lead

University of California, Davis

OTHER